AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Insider Buying Report: SAVA and BCDA
ByAinvest
Tuesday, Sep 23, 2025 10:47 am ET1min read
Two notable insider buys have been reported: Cassava Sciences (SAVA) CEO Richard Barry purchased 237,941 shares for $534,743, and BioCardia (BCDA) Director Simon H. Stertzer bought 398,400 shares for $498,000. Both purchases occurred on Friday and mark the first buy for Barry and the fourth buy for Stertzer in the past year. SAVA is up 19.8% and BCDA is up 11.7% on Tuesday.
Two significant insider buys have been reported this week, contributing to the upward movement of Cassava Sciences (SAVA) and BioCardia (BCDA) stocks. On Friday, Cassava Sciences CEO Richard Barry purchased 237,941 shares at an average price of $2.25 each, while BioCardia Director Simon H. Stertzer bought 398,400 shares at an average price of $1.25 each. Both purchases occurred on the same day and mark the first buy for Barry and the fourth buy for Stertzer in the past year.Cassava Sciences (SAVA)
Cassava Sciences shares are trading higher on Tuesday, with a 19.61% increase to $2.77. The stock has a 52-week high of $33.98 and a 52-week low of $1.15. The insider purchase by CEO Richard Barry is viewed as a vote of confidence in the company's future, following the recent halt in the development of its Alzheimer’s drug, simufilam, after the Phase 3 REFOCUS-ALZ trial failed to meet its primary endpoints [1].
BioCardia (BCDA)
BioCardia shares are also experiencing a rebound, up 11.7% on Tuesday to $1.25. The stock has a 52-week high of $1.63 and a 52-week low of $0.90. Director Simon H. Stertzer's purchase is seen as a positive signal, especially given the company's recent financial challenges and market pressures [2].
Both companies have faced significant market challenges, with Cassava Sciences' stock collapsing by over 91% in the past year due to the trial failure of simufilam, and BioCardia's stock falling 32.38% in the past week. The insider purchases are a sign of optimism among key executives and may indicate a potential turnaround for both companies.
References
[1] https://www.benzinga.com/trading-ideas/movers/25/09/47819841/cassava-sciences-sava-stock-is-surging-tuesday-whats-going-on
[2] https://www.investing.com/news/company-news/biocardia-prices-6-million-public-offering-of-common-stock-and-warrants-93CH-4245076
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet